Skip to main content

Table 2 Baseline characteristics and mortality of norepinephrine- vs. vasopressin-treated patients in SPH1 before and after matching. Sensitivity analysis after exclusion of patients who had underlying NYHA IV CHF

From: Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital

Variable Norepinephrine Vasopressin p
Baseline characteristics norepinephrine- vs. vasopressin-treated patients in SPH1 before matching
 Age (years), X ± SD 60.2 ± 16.3 55.5 ± 15.5 < 0.001
 APACHE II, X ± SD 25.5 ± 8.0 29.0 ± 8.7 < 0.001
 Gender (% male) 61.3 73.1 0.009
 Surgical (%) 28.2 31.0 0.503
 Respiratory (%) 88.6 92.4 0.183
 Renal (%) 68.4 82.8 < 0.001
 Coagulation (%) 23.4 38.0 < 0.001
 Hepatic (%) 13.9 22.8 0.01
 Neurological (%) 64.8 80.0 < 0.001
 Ventilated (%) 92.4 89.0 0.188
 Any chronic disease (%) 41.3 49.7 0.073
 Norepinephrine dose (ug/min) 13.6 ± 15.0 21.8 ± 22.0 < 0.001
Baseline characteristics norepinephrine- vs. vasopressin-treated patients in SPH1 after matching
 Age (years), X ± SD 56.8 ± 14.9 56.1 ± 15.3 0.644
 APACHE II, X ± SD 28.5 ± 8.2 28.8 ± 8.4 0.831
 Gender (% male) 66.4 72.9 0.242
 Surgical (%) 31.4 31.4 1
 Respiratory (%) 92.9 92.1 0.821
 Renal (%) 77.1 82.1 0.299
 Coagulation (%) 28.6 37.9 0.099
 Hepatic (%) 18.6 23.6 0.305
 Neurological (%) 71.4 79.3 0.127
 Ventilated (%) 93.6 89.3 0.2
 Any chronic disease (%) 47.9 48.6 0.905
Mortality of norepinephrine- vs. vasopressin-treated patients in SPH1 after matching
 28-day mortality (%) 46.4 62.9 0.006